We are live on ! Find out more
ATRC icon

AtriCure

141 hedge funds and large institutions have $872M invested in AtriCure in 2019 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 54 increasing their positions, 50 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 50

0.68% less ownership

Funds ownership: 89.24%88.56% (-0.68%)

3% less funds holding

Funds holding: 145141 (-4)

15% less capital invested

Capital invested by funds: $1.03B → $872M (-$157M)

16% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 19

33% less funds holding in top 10

Funds holding in top 10: 64 (-2)

58% less call options, than puts

Call options by funds: $962K | Put options by funds: $2.27M

Holders
141
Holders Change
-4
Holders Change %
-2.76%
% of All Funds
3.09%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.09%
New
16
Increased
54
Reduced
50
Closed
19
Calls
$962K
Puts
$2.27M
Net Calls
-$1.31M
Net Calls Change
-$7.66M

ATRC Hedge Fund Activity: Q3 2019 in Review

141 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in AtriCure (ATRC) for Q3 2019, worth a combined $872M — down 15% from $1.03B a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of ATRC and 16 opened new positions — a net loss of 3 holders — while 50 trimmed existing stakes and 54 added.

The largest buyer was Champlain Investment Partners, opening a new position worth an estimated $19.3M. The largest seller was Hood River Capital Management, exiting entirely with an estimated $12.2M sold.

  • 141 institutional investors held AtriCure (ATRC) as of Q3 2019, down from 145 in Q2 2019.
  • Funds reported $872M of AtriCure stock for Q3 2019, down 15% quarter-over-quarter.
  • 16 funds opened new AtriCure positions in Q3 2019 and 19 closed out, a net change of -3 holders.
  • The largest AtriCure buyer in Q3 2019 was Champlain Investment Partners, an estimated $19.3M added.
  • The largest AtriCure seller in Q3 2019 was Hood River Capital Management, an estimated $12.2M sold.

Based on aggregated 13F filings for Q3 2019.